Suma Ramadas, PhDMedical Affairs
Liz KaneImpactful Strategy
Pat PurcellMeeting Engagement
Joey CohenMedication Adherence
Brenda SnowAuthentic Patient Voice
Stacey GandlerBrand Nourishment
Daniel SontupeMarket Access
Frank BurrellScientific Storytelling
Matthew DurhamOmnidynamic Marketing
David LinetskyPoint-of-Care Marketing
Paul TheisenPatient Acquisition
Matt TurnerPatient Affordability
Bud BilanichSuccess Coach
Amy GilesIncreasing Engagement
Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patientsTranslational studies suggest ...
-- First quarter 2017 EXONDYS 51® (eteplirsen) total net revenues of $64.6 million -- ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email